Oxford Biodynamics
OBD · AIM · Health Care · mcap £16m · 0.1p
| Date | Type | Announcement | Day |
|---|---|---|---|
| 01 Oct 26 | Fundraise | Extension of Timetable in relation to Placing
Oxford BioDynamics Plc (AIM: OBD), the 3D Genomics Company, announced on 10 August 2026 that it had conditionally raised £9.15m through a placing of 9,150,000,000 new ordinary shares (the “Placing Shares”) at a price of |
−5.0% |
| 03 Sep 26 | Orion reveals link between five fatigue conditions
Study finds five major fatigue-related conditions converge on shared regulatory networks when analysed using Oxford BioDynamics' EpiSwitch® Orion platform |
−4.2% | |
| 27 Aug 26 | Board change | Board Appointment
Oxford, UK - 27 August 2026 - Oxford BioDynamics Plc (AIM: OBD), the international biotechnology company advancing personalised healthcare through precision clinical diagnostic tests and EpiSwitch® Orion, its cloud-based |
+0.0% |
| 13 Aug 26 | Partnership with Dubai London Clinics & Hospitals
Oxford BioDynamics partners with Dubai London Clinics & Hospitals to bring EpiSwitch® PSE to the UAE |
+0.0% | |
| 10 Aug 26 | Fundraise | Fundraising, Posting of Circular & Notice of GM
Oxford, UK - 10 August 2026 - Oxford Biodynamics Plc (AIM: OBD), the international biotechnology company advancing personalised healthcare through precision clinical diagnostic tests and EpiSwitch® Orion, its cloud-based |
+9.1% |
| 28 Jul 26 | First commercial agreement for EpiSwitch® Orion
Oxford BioDynamics signs first commercial agreement for its EpiSwitch® Orion 3D genomics discovery platform |
+8.3% | |
| 30 Jun 26 | US contract sales partnership
("OBD" or the "Company" and, together with its subsidiaries, the "Group") |
−33.3% | |
| 30 Jun 26 | Results | Half-year Results
("OBD" or the "Company" and, together with its subsidiaries, the "Group") |
−33.3% |
| 30 Jun 26 | Board change | Appointment of Chief Executive Officer
("OBD" or the "Company" and, together with its subsidiaries, the "Group") |
−33.3% |
| 15 Apr 26 | Board change | Board Appointment
("OBD" or the "Company" and, together with its subsidiaries, the "Group") |
+2.6% |
| 03 Mar 26 | OBD to present at PMWC 2026
("OBD" or the "Company" and, together with its subsidiaries, the "Group") |
+0.0% | |
| 17 Feb 26 | Change of Nominated Adviser
("OBD" or the "Company" and, together with its subsidiaries, the "Group") |
+1.7% | |
| 26 Jan 26 | Board change | Directorate Change
("OBD" or the "Company" and, together with its subsidiaries, the "Group") |
−3.7% |
| 22 Dec 25 | Publication of 2025 Annual Report
("OBD" or the "Company" and, together with its subsidiaries, the "Group") |
+0.0% | |
| 16 Dec 25 | Preliminary Results and Notice of AGM
("OBD" or the "Company" and, together with its subsidiaries, the "Group") |
−4.0% | |
| 22 Oct 25 | Fundraise | Fundraising, Posting of Circular & Notice of GM
The Placing and the Subscriptions (together the "Fundraising") are being carried out at an issue price of £0.003 per Ordinary Share of £0.001 each (the "Issue Price"). |
−39.0% |
| 14 Oct 25 | OBD in New Report on NHS Prostate Cancer Screening
Prostate Cancer Research NHS screening report highlights OBD's EpiSwitch PSE |
+4.8% | |
| 08 Oct 25 | OBD and UEA develop test for Chronic Fatigue
OBD and UEA develop breakthrough diagnostic test for Chronic Fatigue Syndrome |
+12.4% |
Company filings. Not investment advice.